INFILTRATING BLADDER UROTHELIAL CARCINOMA, MICROPAPILLARY VARIANT
Clinical trials for INFILTRATING BLADDER UROTHELIAL CARCINOMA, MICROPAPILLARY VARIANT explained in plain language.
Never miss a new study
Get alerted when new INFILTRATING BLADDER UROTHELIAL CARCINOMA, MICROPAPILLARY VARIANT trials appear
Sign up with your email to follow new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA, MICROPAPILLARY VARIANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
Disease control OngoingThis early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…
Matched conditions: INFILTRATING BLADDER UROTHELIAL CARCINOMA, MICROPAPILLARY VARIANT
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New drug combo targets Hard-to-Treat bladder cancer
Disease control OngoingThis study tests a combination of two drugs, pemetrexed and avelumab, in people with a specific type of advanced bladder cancer that lacks a protein called MTAP. The goal is to see if this treatment can shrink or control the cancer. About 18 participants who have already tried ch…
Matched conditions: INFILTRATING BLADDER UROTHELIAL CARCINOMA, MICROPAPILLARY VARIANT
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC